Clinical Trial Update: A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels [Phase 3]

View source ↗

Summary

This Phase 3 trial update evaluates the TAXUS Liberté paclitaxel-eluting stent for de novo coronary artery lesions in small vessels; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TAXUS Liberté Stent (paclitaxel-eluting stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED